Metformin

How to order Metformin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Metformin on Prescriptsy

Metformin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Metformin is the most widely prescribed medicine for type 2 diabetes mellitus in the United Kingdom and throughout the world.

It belongs to the biguanide class of glucose-lowering medicines and has been in clinical use for over 60 years, making it one of the most extensively studied oral antidiabetic agents available.

NICE recommends metformin as the first-line pharmacological treatment for type 2 diabetes, to be started alongside diet and lifestyle modifications when glycaemic targets are not achieved through lifestyle changes alone.

Metformin is available as standard-release tablets (500 mg, 850 mg, 1,000 mg), modified-release tablets, and an oral solution. It is a prescription-only medicine (POM) in the UK.

Type 2 diabetes affects approximately 4.3 million people in the United Kingdom, with a further 2.4 million estimated to be at high risk of developing the condition.

It is characterised by insulin resistance and progressive beta-cell dysfunction, leading to sustained hyperglycaemia that, over time, causes damage to blood vessels and nerves.

Effective blood glucose management reduces the risk of microvascular complications (retinopathy, nephropathy, neuropathy) and, according to the landmark UK Prospective Diabetes Study (UKPDS), reduces diabetes-related mortality.

This page provides a thorough clinical overview of metformin, including how it works, dosage guidance, side effects, important safety information, and practical advice for patients in the UK.

Important safety information about metformin

• Metformin is a prescription-only medicine. Use it exactly as directed by your prescriber.
• Metformin does not cause hypoglycaemia when used alone, but the risk increases when combined with other diabetes medicines.
• Stop metformin and seek urgent medical advice if you develop symptoms of lactic acidosis: nausea, vomiting, rapid breathing, stomach pain, and muscle cramps.
• Follow sick day rules: stop metformin temporarily if you are unable to eat or drink normally due to illness.
• Have your kidney function tested regularly while taking metformin.

Understanding type 2 diabetes and the role of metformin

Type 2 diabetes develops when the body becomes resistant to the effects of insulin and the pancreas cannot produce enough insulin to overcome this resistance.

Insulin is the hormone that allows glucose from food to enter cells and be used for energy.

In type 2 diabetes, glucose accumulates in the blood, leading to hyperglycaemia.

Over months and years, persistently elevated blood glucose damages small blood vessels in the eyes, kidneys, and nerves (microvascular complications) and contributes to the development of cardiovascular disease (macrovascular complications).

Metformin addresses the underlying pathophysiology of type 2 diabetes by reducing the amount of glucose produced by the liver (hepatic gluconeogenesis) and improving the sensitivity of muscle cells to insulin.

Unlike sulphonylureas or insulin, it does not force the pancreas to produce more insulin, which means it does not cause hypoglycaemia when used on its own and does not promote weight gain.

These properties, combined with its proven cardiovascular benefit and decades of safety data, are why metformin is universally recommended as first-line therapy.

How metformin works: mechanism of action

Metformin exerts its glucose-lowering effect through several complementary mechanisms. The primary action is the suppression of hepatic glucose production.

In type 2 diabetes, the liver produces excessive amounts of glucose, even when blood glucose levels are already elevated.

Metformin reduces this overproduction by activating AMP-activated protein kinase (AMPK), a cellular energy sensor that inhibits the enzymes responsible for gluconeogenesis.

This effect accounts for the majority of metformin's glucose-lowering activity.

The second mechanism is the enhancement of insulin-mediated glucose uptake in skeletal muscle.

By improving insulin sensitivity at the cellular level, metformin helps muscle cells absorb more glucose from the blood after meals.

The third mechanism is a modest delay in the absorption of glucose from the gastrointestinal tract, which reduces postprandial (after-meal) glucose spikes.

Additionally, metformin reduces circulating free fatty acid concentrations, which contributes to improved insulin sensitivity because elevated free fatty acids impair insulin signalling.

Metformin also has beneficial effects beyond glucose control. It improves lipid profiles by lowering LDL cholesterol and triglycerides.

The UKPDS demonstrated that metformin reduced the risk of myocardial infarction by 39% in overweight patients with type 2 diabetes, an effect that was independent of its glucose-lowering action and suggested direct cardiovascular protective properties.

Clinical evidence and UK prescribing guidance

The evidence base for metformin is extensive.

The UKPDS, published in 1998, was the first major trial to demonstrate that metformin reduced diabetes-related endpoints and all-cause mortality in overweight patients with newly diagnosed type 2 diabetes.

This landmark finding established metformin as the preferred initial therapy and has been reinforced by subsequent meta-analyses and real-world data.

NICE guideline NG28 (Type 2 diabetes in adults: management) recommends offering standard-release metformin as initial drug treatment, titrated gradually to minimise gastrointestinal side effects.

If standard-release metformin is not tolerated, NICE recommends trying modified-release metformin before considering alternative agents.

If metformin alone is insufficient to achieve the individualised HbA1c target (usually 48 mmol/mol or 53 mmol/mol depending on circumstances), NICE advises dual therapy by adding a second agent such as a sulphonylurea, a DPP-4 inhibitor, pioglitazone, an SGLT2 inhibitor, or a GLP-1 receptor agonist.

The choice of second-line agent depends on individual patient factors including cardiovascular risk, weight, renal function, and hypoglycaemia risk.

The ADA/EASD consensus report similarly positions metformin as first-line therapy, with recent updates emphasising the importance of selecting add-on agents with proven cardiovascular or renal benefit (particularly SGLT2 inhibitors and GLP-1 receptor agonists) in patients with established cardiovascular disease or chronic kidney disease.

Metformin in context: comparing type 2 diabetes treatments

Understanding how metformin compares with other glucose-lowering medicines helps explain why it remains the preferred first-line option.

Sulphonylureas (gliclazide, glimepiride) are effective and inexpensive but cause hypoglycaemia and weight gain.

DPP-4 inhibitors (sitagliptin, linagliptin) are weight-neutral and well tolerated but have modest glucose-lowering efficacy and no proven cardiovascular benefit.

Pioglitazone improves insulin sensitivity and has durable glucose-lowering effects but causes weight gain, fluid retention, and an increased risk of heart failure and fractures.

SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) promote glucose excretion through the kidneys, cause weight loss, reduce blood pressure, and have proven cardiovascular and renal benefits, but they increase the risk of genital thrush and urinary tract infections.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) cause significant weight loss and have cardiovascular benefits but require injection (except oral semaglutide), are expensive, and commonly cause nausea.

Metformin offers a unique combination of efficacy, safety, weight neutrality, cardiovascular benefit, and very low cost. Generic metformin is one of the least expensive medicines in the BNF, costing the NHS just a few pounds per month per patient.

Off-label uses of metformin

Metformin is used off-label for several conditions beyond type 2 diabetes.

In polycystic ovary syndrome (PCOS), metformin improves insulin sensitivity and can help regulate menstrual cycles, reduce androgen levels, and support ovulation.

While NICE does not recommend metformin as first-line for PCOS (clomifene is preferred for ovulation induction), it may be used in combination or when clomifene is ineffective.

Metformin is also used in gestational diabetes when blood glucose targets are not met with diet and exercise.

NICE supports its use as a first-line pharmacological option in gestational diabetes.

Research into metformin's potential role in cancer prevention, anti-ageing, and non-alcoholic fatty liver disease is ongoing but not yet sufficient to support clinical recommendations.

Dosage and administration

Standard-release metformin is started at 500 mg once or twice daily, taken with or after meals.

The dose is increased gradually (typically every 1 to 2 weeks) based on blood glucose response and tolerability, up to a maximum of 2,000 mg daily in divided doses.

Modified-release tablets are taken once daily with the evening meal, starting at 500 mg and increasing to a maximum of 2,000 mg daily.

Tablets should be swallowed whole with water. Do not crush, chew, or break modified-release tablets.

Dose reduction is required if the eGFR is between 30 and 44 mL/min/1.73m2 (maximum 1,000 mg daily), and metformin must be stopped if the eGFR falls below 30.

Renal function should be checked before starting treatment, at least annually, and more frequently (every 3 to 6 months) if the eGFR is below 45 or declining.

Side effects of metformin

Common side effects

Gastrointestinal symptoms are the most frequently reported side effects and the main reason patients discontinue treatment.

Nausea, diarrhoea, abdominal pain, bloating, flatulence, and a metallic taste affect up to 25% of patients at some point during treatment.

These effects are dose-related, usually occur at the start of therapy or after dose increases, and often improve over several weeks.

Strategies to minimise GI side effects include starting at the lowest dose, titrating slowly, taking metformin with meals, and switching to modified-release tablets if standard-release is poorly tolerated.

Vitamin B12 deficiency

Long-term metformin use (typically more than 3 to 4 years) is associated with reduced vitamin B12 absorption in the terminal ileum.

This can lead to clinically significant vitamin B12 deficiency in an estimated 5 to 10% of long-term users.

Symptoms include fatigue, peripheral neuropathy (which may be mistaken for diabetic neuropathy), cognitive impairment, and macrocytic anaemia.

Patients taking metformin should be aware of these symptoms and have B12 levels checked if they develop. Some clinicians advocate routine annual screening.

Lactic acidosis

Lactic acidosis is the most serious adverse effect of metformin, but it is extremely rare (fewer than 10 cases per 100,000 patient-years).

It occurs almost exclusively when metformin accumulates to toxic levels because of renal impairment, severe hepatic dysfunction, tissue hypoxia (severe heart failure, respiratory failure, sepsis), or extreme dehydration.

Symptoms include nausea, vomiting, abdominal pain, hyperventilation, muscle cramps, hypothermia, and progressive drowsiness. Lactic acidosis has a high mortality rate and requires emergency treatment.

Call 999 immediately if these symptoms occur.

When to seek medical advice

Contact your GP or call NHS 111 if you experience persistent GI symptoms that do not improve after several weeks, numbness or tingling in your hands or feet, unusual fatigue, or signs of B12 deficiency.

Call 999 if you develop symptoms of lactic acidosis (severe nausea, rapid deep breathing, muscle cramps, drowsiness).

Report suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Metformin is contraindicated in patients with severe renal impairment (eGFR below 30 mL/min/1.73m2), hepatic failure, diabetic ketoacidosis, conditions predisposing to tissue hypoxia (decompensated cardiac failure, respiratory failure, recent myocardial infarction, severe infection with sepsis), chronic alcohol misuse, and acute alcohol intoxication.

Kidney function monitoring

Renal function (eGFR) must be checked before starting metformin, at least annually during treatment, and every 3 to 6 months if the eGFR is below 45 or declining.

If the eGFR falls below 30, metformin must be stopped. Acute kidney injury, caused by dehydration, infection, or nephrotoxic drugs, can lead to dangerous metformin accumulation.

Sick day rules

During acute illness involving vomiting, diarrhoea, fever, or an inability to maintain normal fluid intake, metformin should be temporarily stopped.

Dehydration reduces renal perfusion and can cause acute kidney injury, increasing the risk of metformin accumulation and lactic acidosis.

Resume metformin only when eating and drinking normally and feeling well. All patients prescribed metformin should receive clear counselling on sick day rules, ideally in writing.

Contrast media and surgery

Metformin should be withheld before and for 48 hours after the administration of iodinated contrast media (used in CT scans, angiography) because of the risk of contrast-induced nephropathy leading to metformin accumulation.

It should also be withheld for 48 hours before and after general anaesthesia. Renal function should be confirmed as stable before restarting.

Alcohol

Excessive alcohol intake increases the risk of lactic acidosis by impairing hepatic lactate metabolism and may potentiate the hypoglycaemic effect of metformin when combined with other diabetes medicines.

Patients should drink within the UK Chief Medical Officers' low-risk guidelines (no more than 14 units per week, spread across 3 or more days).

Pregnancy and breastfeeding

Metformin is used in pregnancy for gestational diabetes under specialist guidance. NICE recommends it as a pharmacological option when diet and exercise are insufficient to control blood glucose.

It crosses the placenta, but available evidence is reassuring regarding fetal safety. Metformin is present in breast milk in small quantities and is generally considered compatible with breastfeeding.

Discuss with your diabetes team or obstetrician.

How to get metformin in the UK

Metformin is a prescription-only medicine. You can obtain a prescription from your GP, hospital diabetes clinic, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Many patients with diabetes in England are eligible for a medical exemption certificate, which entitles them to free prescriptions for all medicines, not just diabetes treatments.

You can apply for an exemption certificate through your GP practice.

Lifestyle advice for patients taking metformin

Metformin works best as part of a comprehensive approach to diabetes management that includes healthy eating, regular physical activity, and weight management.

The NHS recommends at least 150 minutes of moderate-intensity aerobic activity per week (brisk walking, cycling, swimming) plus resistance exercises on two or more days per week.

A balanced diet rich in whole grains, vegetables, lean protein, and healthy fats, with reduced intake of refined carbohydrates and sugary drinks, supports blood glucose control.

Attend all scheduled diabetes reviews, including annual eye screening (NHS Diabetic Eye Screening Programme), foot checks, and kidney function tests.

Monitor your blood glucose at home if advised by your diabetes team, and record your readings to discuss at clinic appointments.

Smoking cessation is strongly recommended, as smoking substantially increases cardiovascular risk, which is already elevated in people with diabetes.

Sources

• Metformin 500mg Tablets, Summary of Product Characteristics (EMC)
• Metformin hydrochloride, British National Formulary (BNF)
• NICE NG28: Type 2 diabetes in adults, management
• Metformin, NHS
• MHRA Yellow Card Scheme